Advertisement

Charles River Laboratories International Inc. will seek to off-load under-performing assets, including two facilities.

The Wilmington-based pharmaceutical and biotech services company said it would seek “strategic alternatives” for a U.S. Phase 1 research clinic and a pre-clinical research facility in China. The company said this would eliminate $10 million in losses from the two facilities.

SOURCE

Advertisement
Advertisement